• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Cabaletta Bio Inc.

    8/12/25 9:04:13 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CABA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 6)


    Cabaletta Bio, Inc.

    (Name of Issuer)


    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)


    12674W109

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    12674W109


    1Names of Reporting Persons

    Adage Capital Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,002,580.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,002,580.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,002,580.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA, PN

    Comment for Type of Reporting Person:  Includes 172,822 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.


    SCHEDULE 13G

    CUSIP No.
    12674W109


    1Names of Reporting Persons

    Robert Atchinson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,002,580.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,002,580.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,002,580.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Includes 172,822 shares of Common Stock issuable upon exercise of warrants.


    SCHEDULE 13G

    CUSIP No.
    12674W109


    1Names of Reporting Persons

    Phillip Gross
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,002,580.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,002,580.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,002,580.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Includes 172,822 shares of Common Stock issuable upon exercise of warrants.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Cabaletta Bio, Inc.
    (b)Address of issuer's principal executive offices:

    2929 Arch Street, Suite 600, Philadelphia, PA 19104
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Adage Capital Management, L.P., a Delaware limited partnership ("ACM"), as the investment manager of Adage Capital Partners, L.P., a Delaware limited partnership ("ACP"), with respect to the shares of common stock, par value $0.00001 per share ("Common Stock") of Cabaletta Bio, Inc., a Delaware corporation (the "Company") and shares of Common Stock issuable upon exercise of warrants directly held by ACP; (ii) Robert Atchinson ("Mr. Atchinson"), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACA"), managing member of Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACPGP"), general partner of ACP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company ("ACPLLC"), general partner of ACM, with respect to the shares of Common Stock and shares of Common Stock issuable upon exercise of warrants directly held by ACP; and (iii) Phillip Gross ("Mr. Gross"), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the shares of Common Stock and shares of Common Stock issuable upon exercise of warrants directly held by ACP. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.
    (c)Citizenship:

    ACM is a limited partnership organized under the laws of the State of Delaware. Messrs. Gross and Atchinson are citizens of the United States.
    (d)Title of class of securities:

    Common Stock, par value $0.00001 per share
    (e)CUSIP No.:

    12674W109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 89,943,101 shares of Common Stock, reported to be outstanding in the Company's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on June 12, 2025 and the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 12, 2025, after giving effect to the completion of the offering, as described therein, and assumes the reported warrants held by ACP.
    (b)Percent of class:

    9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a).
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Adage Capital Management, L.P.
     
    Signature:/s/ Robert Atchinson
    Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
    Date:08/12/2025
     
    Robert Atchinson
     
    Signature:/s/ Robert Atchinson
    Name/Title:Robert Atchinson, individually
    Date:08/12/2025
     
    Phillip Gross
     
    Signature:/s/ Phillip Gross
    Name/Title:Phillip Gross, individually
    Date:08/12/2025
    Get the next $CABA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CABA

    DatePrice TargetRatingAnalyst
    12/20/2024$15.00 → $6.00Outperform → In-line
    Evercore ISI
    12/19/2024$12.00 → $6.00Overweight → Equal Weight
    Wells Fargo
    10/10/2024$10.00Buy
    UBS
    2/5/2024$36.00Buy
    Jefferies
    11/29/2023$38.00Outperform
    William Blair
    10/24/2023$40.00Overweight
    Cantor Fitzgerald
    10/19/2023$31.00Buy
    Stifel
    9/5/2023$22.00Buy
    Citigroup
    More analyst ratings

    $CABA
    SEC Filings

    View All

    SEC Form EFFECT filed by Cabaletta Bio Inc.

    EFFECT - Cabaletta Bio, Inc. (0001759138) (Filer)

    8/18/25 12:15:23 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Cabaletta Bio Inc.

    SCHEDULE 13G - Cabaletta Bio, Inc. (0001759138) (Subject)

    8/14/25 5:29:13 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Cabaletta Bio Inc.

    SCHEDULE 13G - Cabaletta Bio, Inc. (0001759138) (Subject)

    8/14/25 3:02:09 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CABA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cabaletta Bio downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Cabaletta Bio from Outperform to In-line and set a new price target of $6.00 from $15.00 previously

    12/20/24 7:29:05 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cabaletta Bio downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Cabaletta Bio from Overweight to Equal Weight and set a new price target of $6.00 from $12.00 previously

    12/19/24 7:31:17 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS initiated coverage on Cabaletta Bio with a new price target

    UBS initiated coverage of Cabaletta Bio with a rating of Buy and set a new price target of $10.00

    10/10/24 7:27:43 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CABA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Simon Mark

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    6/9/25 8:28:01 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Brun Scott C.

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    6/9/25 8:22:15 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Bollard Catherine

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    6/9/25 8:20:03 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CABA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

    – Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in the RESET™ clinical development program from over 70 clinical sites as of July 31, 2025, with expansion phase enrollment continuing – – FDA meetings to align on the next wave of registrational cohorts for rese-cel anticipated in 3Q25 for lupus, 4Q25 for systemic sclerosis and 1H26 for myasthenia gravis – – Rese-cel clinical data presented at the EULAR 2025 Congress reinforce compelling clinical responses with nearly all patients off immunomodulatory medications and steroids; favorable risk-be

    8/7/25 7:30:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cabaletta Bio Announces Pricing of Public Offering of Securities

    PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of its common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 10,800,000 shares of its common stock and accom

    6/11/25 9:54:40 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cabaletta Bio Announces Proposed Public Offering of Securities

    PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in li

    6/11/25 6:15:28 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CABA
    Leadership Updates

    Live Leadership Updates

    View All

    Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

    – Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences – PHILADELPHIA, July 24, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello has over 35 years of experience in the life sciences industry, including specific expertise in CD19-CAR T therapy, where she most recently served as the Chief Commercial Officer of Kite Pharma, Inc. between 20

    7/24/23 8:00:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

    Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru

    6/20/23 8:00:00 AM ET
    $CABA
    $FBRX
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel

    PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been appointed general counsel. "We are very pleased to welcome Mike to the executive team. His experience with a wide range of strategic legal and corporate matters within the life sciences industry will complement the management team as we advance clinical development for DSG3-CAART in our DesCAARTes™ trial, and further develop follow-on candidates from our deep pipeline of precision therapies for pati

    9/7/21 8:00:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CABA
    Financials

    Live finance-specific insights

    View All

    Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

    – CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myositis patients with up to six months of follow-up; first SSc patient demonstrated an emerging, drug-free clinical response – – All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 infusion and through the follow-up period – – Consistent and complete B cell depletion observed in all patients within the first month after CABA-201 infusion; evidence of transitional naïve B cell repopula

    11/18/24 7:00:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

    – Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 – – 16 patients enrolled with 10 patients dosed as of November 12 across the RESET™ clinical development program; 40 U.S. clinical sites actively recruiting patients – – Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201 – – Clinical development expanding efficiently into Europe with EMA CTA authorization for CABA-201 received in lupus; Gerwin Winter appointed as Senior VP and Head of International – – Cash, cash

    11/14/24 7:00:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

    – No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both patients by day 15 post-infusion – – Improvements in both patients' specific disease measures, consistent with academic experience of a similar 4-1BB CD19-CAR T, suggest emerging clinical benefit with CABA-201 while discontinuing all disease-specific therapies other than a planned steroid taper in one patient – – Immature, naïve B cell repopulation in first IMNM patient observed at week 8 consistent with a potential immu

    6/14/24 2:00:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CABA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/5/24 4:50:19 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/5/24 3:36:55 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care